ACROMEGALY AND COMORBIDITY: DIAGNOSIS AND TREATMENT


DOI: https://dx.doi.org/10.18565/pharmateca.2018.4.23-26

M.B. Antsiferov (1), L.I. Astafyeva (2)

1 Endocrinological Dispensary of the Moscow Healthcare Department, Moscow, Russia; 2 SRI of Neurosurgery n.a. Acad. N.N. Burdenko, Moscow, Russia
Acromegaly is a severe chronic neuroendocrine disease, accompanied by such concomitant conditions as diabetes mellitus, cardiovascular, respiratory, and musculoskeletal disorders, and an increase in the number of neoplasms. Development of these conditions is associated with an increase in the growth hormone and insulin-like growth factor 1 levels. Therefore, the pathogenetic treatment of acromegaly, namely the use of somatostatin analogues, remains the main method of treatment and prevention of concomitant diseases. Nevertheless, in a number of cases, additional symptomatic treatment is necessary in persisting symptoms and controlled course of the disease.
Keywords: acromegaly, comorbidity, somatostatin analogues, lanreotide

About the Autors


Corresponding author: L.I. Astafyeva – MD, Doctor at the Neurological Department SRI of Neurosurgery n.a. Acad. N.N. Burdenko, Moscow, Russia; tel. 8 (499) 972-86-91


Бионика Медиа